Pathogenesis and treatment of Parkinson's disease;Mecanismes et traitements de la maladie de Parkinson

Revue du Praticien

Volumn 47, Issue 10, 1997, Pages 1068-1075

  Pollak, Pierre ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; LISURIDE; LISURIDE MALEATE; ORPHENADRINE; PIRIBEDIL; SELEGILINE; TRIHEXYPHENIDYL; TROPATEPINE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; DOPAMINE;

DOPAMINERGIC SYSTEM; DRUG EFFICACY; HUMAN; PARKINSON DISEASE; PATHOGENESIS; SHORT SURVEY; ARTICLE; METABOLISM; NERVE CELL;

ANTIPARKINSON AGENTS; DOPAMINE; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE;

EID: 0030923236     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (30)

1. Jellinger KA. Pathology of Parkinson's disease: Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14: 153-97.
2. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
3. Agid Y, Ruberg M, Raisman R, Hirsch E, Javoy-Agid F. The biochemistry of Parkinson's disease. In: Stern GM (ed). Parkinson's disease. London: Chapman and Hall Ltd, 1990: 99-125.
4. Hirsch E. Why are catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 1992; 32: S88-S93.
5. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992; 42: 2241-50.
6. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease. A critical appraisal. Mov Disord 1994; 9: 125-38.
7. Mizuno Y, Ikebe S, Mochizuki H, Matumine H, Kondo T. Etiology and pathogenesis of Parkinson's disease. Brain Nerve 1996; 48: 5-17.
8. Ben Shiomo Y. How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996; 61 : 4-16.
9. Polymeropoulos MH, Higgins JJ, Golbe LI et al. Mapping of a gene for Parkinson's disease to chromosome 4 q2l-q23. Science 1996; 274: 1197-9.
10. Marsden CD. Neurophysiology. In: Stern GM (ed). Parkinson's disease. London : Chapman and Hall Ltd, 1990: 57-98.
11. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-71.
12. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-5.
13. Bergman H, Wichmann T, Karmon B, DeLong M. The primate subthalamic nucleus. II. Neural activity in the MPTP model of Parkinsonism. J Neurophysiol 1994; 72: 507-20.
14. Mouradian MM, Chase TN. Improved dopaminergie therapy of Parkinson's disease, in : Marsden CD, Fahn S (eds); Movement Disorders 3. Oxford : Butterworth-Heinemann Ltd, 1994 : 181-99.
15. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459.
16. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: lmposing pharmacological law and order. Ann Neurol 1996; 39: 561-73.
17. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6: 889-97.
18. Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979; i: 570-2.
19. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-81.
20. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995; 310: 575-9.
21. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93.
22. Lees AJ. Dopamine agonists in Parkinson's disease. A look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121-8.
23. Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson's disease. Biomed Pharmacother 1995; 49: 197-209.
24. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 47 (suppl 3): S 161-S 170.
25. Limousin P, Pollak P, Gervason CL, Hommel M, Perret JE. Prolongation of clinical response to levodopa acute administration by Ro 40-7592, a COMT inhibitor in Parkinson's disease. Lancet 1993; 341: 1605.
26. Benabid AL, Pollak P, Gervason CL et al. Long-term suppression of tremor by stimulation of the ventral intermediate thalamic nucleus. Lancet 1991 ; i: 403-6.
27. Lozano A, Lang A, Galvez-Jimenez N et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-7.
28. Limousin P, Pollak P, Benazzouz A et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-5.
29. Pollak P, Benabid AL, Limousin P, Krack P. Treatment of Parkinson's disease. New surgical treatment strategies. Eur Neurol 1996; 36: 396-408.
30. Widner H, Rehncrona S. Transplantation and surgical treatment of parkinsonian syndromes. Curr Opin Neurol Neurosurg 1993; 6: 344-9.